Kura Oncology Stock Cash Per Share
| KURA Stock | USD 19.62 0.44 2.19% |
Kura Oncology fundamentals help investors to digest information that contributes to Kura Oncology's financial success or failures. It also enables traders to predict the movement of Kura Stock. The fundamental analysis module provides a way to measure Kura Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kura Oncology stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 5.79 | 3.15 |
Kura | Cash Per Share |
Kura Oncology Company Cash Per Share Analysis
Kura Oncology's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Kura Oncology Cash Per Share | 6.73 X |
Most of Kura Oncology's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kura Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kura Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Kura Oncology is extremely important. It helps to project a fair market value of Kura Stock properly, considering its historical fundamentals such as Cash Per Share. Since Kura Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kura Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kura Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Kura Cash Per Share Historical Pattern
Today, most investors in Kura Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kura Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Kura Oncology cash per share as a starting point in their analysis.
Kura Oncology Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
Kura Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, Kura Oncology has a Cash Per Share of 6.73 times. This is 54.71% higher than that of the Biotechnology sector and 55.43% higher than that of the Health Care industry. The cash per share for all United States stocks is 34.33% lower than that of the firm.
Kura Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in cash per share category among related companies.
Kura Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 1.12 B | ||||
| Shares Outstanding | 76.18 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 98.93 % | ||||
| Number Of Shares Shorted | 10.12 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 3.73 X | ||||
| EBITDA | (164.96 M) | ||||
| Net Income | (152.63 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 17.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 5.34 X | ||||
| Cash Flow From Operations | (124.82 M) | ||||
| Short Ratio | 11.66 X | ||||
| Earnings Per Share | (2.08) X | ||||
| Target Price | 30.25 | ||||
| Number Of Employees | 142 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 1.54 B | ||||
| Total Asset | 448.94 M | ||||
| Retained Earnings | (721.44 M) | ||||
| Working Capital | 397.22 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
| Net Asset | 448.94 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.